PORTLAND, OR--(Marketwire - December 03, 2008) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced the filing of an Investigational New Drug application with the U.S. Food and Drug Administration for a clinical trial evaluating the Company’s antisense drug AVI-6002 for the treatment of Ebola virus. AVI plans to conduct the trial as part of its continued collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID). Preclinical results of AVI-6002 demonstrated a reproducible and high rate of survival in non-human primates challenged with a lethal infection of Ebola.
